Hims & Hers Health (NYSE:HIMS) Coverage Initiated by Analysts at BTIG Research

BTIG Research started coverage on shares of Hims & Hers Health (NYSE:HIMS) in a report issued on Tuesday, Marketbeat reports. The brokerage issued a buy rating and a $35.00 price objective on the stock.

Several other equities analysts have also recently weighed in on HIMS. Bank of America cut Hims & Hers Health from a “buy” rating to an “underperform” rating and dropped their price objective for the company from $32.00 to $18.00 in a research note on Thursday, November 14th. TD Cowen restated a “buy” rating and set a $28.00 price target on shares of Hims & Hers Health in a report on Wednesday, November 20th. Canaccord Genuity Group increased their price objective on shares of Hims & Hers Health from $28.00 to $38.00 and gave the company a “buy” rating in a research note on Monday, December 2nd. Piper Sandler boosted their target price on Hims & Hers Health from $21.00 to $24.00 and gave the stock a “neutral” rating in a research note on Monday. Finally, Morgan Stanley assumed coverage on Hims & Hers Health in a research report on Tuesday, December 17th. They set an “overweight” rating and a $42.00 price target for the company. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and eight have given a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $24.80.

Hims & Hers Health Trading Up 2.6 %

Hims & Hers Health stock opened at $27.61 on Tuesday. The firm has a market capitalization of $6.03 billion, a price-to-earnings ratio of 62.75 and a beta of 1.31. The firm’s fifty day moving average price is $26.84 and its two-hundred day moving average price is $21.57. Hims & Hers Health has a 1-year low of $8.14 and a 1-year high of $35.02.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings results on Monday, November 4th. The company reported $0.32 earnings per share for the quarter, beating the consensus estimate of $0.06 by $0.26. The business had revenue of $401.56 million for the quarter, compared to analysts’ expectations of $382.20 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The firm’s revenue for the quarter was up 77.1% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.04) EPS. On average, research analysts forecast that Hims & Hers Health will post 0.29 EPS for the current year.

Insider Transactions at Hims & Hers Health

In related news, insider Michael Chi sold 2,054 shares of the stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $33.56, for a total transaction of $68,932.24. Following the sale, the insider now owns 184,947 shares of the company’s stock, valued at approximately $6,206,821.32. This represents a 1.10 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Soleil Boughton sold 2,339 shares of Hims & Hers Health stock in a transaction dated Tuesday, October 15th. The shares were sold at an average price of $20.41, for a total value of $47,738.99. Following the transaction, the insider now directly owns 172,274 shares of the company’s stock, valued at $3,516,112.34. The trade was a 1.34 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 1,333,446 shares of company stock worth $34,175,197 over the last quarter. Corporate insiders own 17.71% of the company’s stock.

Institutional Trading of Hims & Hers Health

A number of hedge funds and other institutional investors have recently bought and sold shares of HIMS. Renaissance Technologies LLC grew its position in shares of Hims & Hers Health by 113.1% during the 2nd quarter. Renaissance Technologies LLC now owns 6,039,408 shares of the company’s stock valued at $121,936,000 after purchasing an additional 3,205,108 shares in the last quarter. State Street Corp grew its position in Hims & Hers Health by 4.7% during the third quarter. State Street Corp now owns 4,626,543 shares of the company’s stock worth $85,221,000 after buying an additional 206,078 shares in the last quarter. Geode Capital Management LLC increased its stake in Hims & Hers Health by 12.7% in the 3rd quarter. Geode Capital Management LLC now owns 4,289,549 shares of the company’s stock worth $79,029,000 after acquiring an additional 482,177 shares during the last quarter. Wellington Management Group LLP raised its holdings in shares of Hims & Hers Health by 34.5% in the 3rd quarter. Wellington Management Group LLP now owns 3,444,414 shares of the company’s stock valued at $63,446,000 after acquiring an additional 883,230 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its position in shares of Hims & Hers Health by 15.1% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,667,422 shares of the company’s stock valued at $30,714,000 after acquiring an additional 218,566 shares during the last quarter. Institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.